Nutarniq Corp.

Nutarniq Corp. develops targeted nutritional therapies for chronic diseases and disease complications. Nutarniq’s flagship product, Frontline Neuropathy, was developed by CEO Dr. Evan Lewis PhD, from the first clinical trial to show nerve regeneration in people with diabetes and nerve damage. Frontline Neuropathy contains all of the pro-nerve fats that support nerve health and regeneration.